A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability |
| |
Authors: | Tompkins Van S Hagen Jussara Frazier April A Lushnikova Tamara Fitzgerald Matthew P di Tommaso Anne Ladeveze Veronique Domann Frederick E Eischen Christine M Quelle Dawn E |
| |
Institution: | Department of Pharmacology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, 52242-1109, USA, and the Laboratoire de Genetique Cellulaire et Moleculaire, UPRES EA2622, Centre Hospitalier Universitaire de Poitiers, France. |
| |
Abstract: | The ARF tumor suppressor signals through p53 and other poorly defined anti-proliferative pathways to block carcinogenesis. In a search for new regulators of ARF signaling, we discovered a novel nuclear protein that we named NIAM (nuclear interactor of ARF and MDM2) for its ability to bind both ARF and the p53 antagonist MDM2. NIAM protein is normally expressed at low to undetectable levels in cells because of, at least in part, MDM2-mediated ubiquitination and proteasomal degradation. When reintroduced into cells, NIAM activated p53, caused a G1 phase cell cycle arrest, and collaborated with ARF in an additive fashion to suppress proliferation. Notably, NIAM retains growth inhibitory activity in cells lacking ARF and/or p53, and knockdown experiments revealed that it is not essential for ARF-mediated growth inhibition. Thus, NIAM and ARF act in separate anti-proliferative pathways that intersect mechanistically and suppress growth more effectively when jointly activated. Intriguingly, silencing of NIAM accelerated chromosomal instability, and microarray analyses showed reduced NIAM mRNA expression in numerous primary human tumors. This study identifies a novel protein with tumor suppressor-like behaviors and functional links to ARF-MDM2-p53 signaling. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|